ライフサイエンスコーパス: macrophage activation syndrome

1 ndrome (of whom 2 eventually developed overt macrophage activation syndrome).

2 e into a life-threatening condition known as macrophage activation syndrome.

3 sCD163 are promising diagnostic markers for macrophage activation syndrome.

4 comparable with those in patients with acute macrophage activation syndrome.

5 also help identify patients with subclinical macrophage activation syndrome.

6 requently associated with the development of macrophage activation syndrome.

7 nd the relationship between systemic JIA and macrophage activation syndrome.

8 d (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome.

9 ted intravascular coagulation as features of macrophage activation syndrome.

10 ses, disturbances in cytokine signaling, and macrophage activation syndromes.

11 rheumatoid arthritis is the association with macrophage activation syndrome, a life-threatening compl

12 is trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fe

13 such dysregulation and the relation between macrophage activation syndrome and hemophagocytic lympho

14 urrent understanding of the relation between macrophage activation syndrome and other clinically simi

15 63 levels in sera from 7 patients with acute macrophage activation syndrome complicating systemic JIA

16 m sIL-2Ralpha and sCD163 in diagnosing acute macrophage activation syndrome complicating systemic juv

17 Hence, sepsis patients with macrophage activation syndrome features may benefit from

18 ospective randomized trial using features of macrophage activation syndrome for mortality risk strati

19 tin levels (including those with subclinical macrophage activation syndrome) from those with normal o

20 Clinically, macrophage activation syndrome has strong similarities w

21 ut so are cytokines that are associated with macrophage activation syndrome/hemophagocytic lymphohist

22 on to the successful use of cyclosporine for macrophage activation syndrome in JRA.

23 g can be a useful tool for identifying early macrophage activation syndrome in patients with systemic

24 assification, pathogenesis and management of macrophage activation syndrome in systemic onset juvenil

25 to further elucidate the pathophysiology of macrophage activation syndrome in systemic onset juvenil

26 s of perforin expression may be a feature of macrophage activation syndrome in systemic-onset juvenil

27 ght contribute to the increased incidence of macrophage activation syndrome in these patients.

28 elated with clinical features of established macrophage activation syndrome, including ferritin level

29 Macrophage activation syndrome is a life-threatening com

30 Macrophage activation syndrome is characterized by an ov

31 Macrophage activation syndrome is the rheumatic disease-

32 Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are 2 similar disea

33 hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are both characteri

34 The deadly macrophage activation syndrome (MAS) constitutes one of

35 features of HLH, using modified HLH-2004 and macrophage activation syndrome (MAS) criteria.

36 Macrophage activation syndrome (MAS) is a devastating cy

37 Macrophage activation syndrome (MAS) is an acute episode

38 The pathogenesis of macrophage activation syndrome (MAS) is not clearly unde

39 Macrophage activation syndrome (MAS), a major cause of m

40 hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS).

41 auses early-onset recurrent fever flares and macrophage activation syndrome (MAS).

42 mphohistiocytosis (HLH), and the HLH-sibling macrophage activation syndrome (MAS).

43 both hemophagocytic lymphohistiocytosis and macrophage activation syndrome, natural killer and cytot

44 The macrophage activation syndrome occurred in 7 patients; i

45 IA, 5 of whom showed evidence of subclinical macrophage activation syndrome (of whom 2 eventually dev

46 Two of these 5 patients developed overt macrophage activation syndrome several months later.

47 an level of sIL-2Ralpha in the patients with macrophage activation syndrome was 19,646 pg/ml (interqu

48 the median level of sCD163 in patients with macrophage activation syndrome was 23,000 ng/ml (IQR 14,